🚀 VC round data is live in beta, check it out!
Abivax Valuation Multiples
Discover revenue and EBITDA valuation multiples for Abivax and similar public comparables like Praxis Precision Medicines, Kyowa Kirin, Fosun Pharma, Huadong Medicine and more.
Abivax Overview
About Abivax
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
Founded
2013
HQ
Employees
69
Website
Sectors
Financials (LTM)
EV
$9B
Abivax Financials
Abivax reported last 12-month revenue of $5M and negative EBITDA of ($251M).
In the same LTM period, Abivax generated $5M in gross profit, ($251M) in EBITDA losses, and had net loss of ($368M).
Revenue (LTM)
Abivax P&L
In the most recent fiscal year, Abivax reported revenue of $5M and EBITDA of ($245M).
Abivax expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $5M | XXX | $5M | XXX | XXX | XXX |
| Gross Profit | $5M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($251M) | XXX | ($245M) | XXX | XXX | XXX |
| EBITDA Margin | (5036%) | XXX | (4600%) | XXX | XXX | XXX |
| EBIT Margin | (5717%) | XXX | (5250%) | XXX | XXX | XXX |
| Net Profit | ($368M) | XXX | ($388M) | XXX | XXX | XXX |
| Net Margin | (7386%) | XXX | (7287%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Abivax Stock Performance
Abivax has current market cap of $9B, and enterprise value of $9B.
Market Cap Evolution
Abivax's stock price is $117.11.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9B | $9B | 0.0% | XXX | XXX | XXX | $-4.91 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAbivax Valuation Multiples
Abivax trades at 1730.1x EV/Revenue multiple, and (34.4x) EV/EBITDA.
EV / Revenue (LTM)
Abivax Financial Valuation Multiples
As of March 30, 2026, Abivax has market cap of $9B and EV of $9B.
Equity research analysts estimate Abivax's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Abivax has a P/E ratio of (25.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $9B | XXX | $9B | XXX | XXX | XXX |
| EV (current) | $9B | XXX | $9B | XXX | XXX | XXX |
| EV/Revenue | 1730.1x | XXX | 1618.7x | XXX | XXX | XXX |
| EV/EBITDA | (34.4x) | XXX | (35.2x) | XXX | XXX | XXX |
| EV/EBIT | (30.3x) | XXX | (30.8x) | XXX | XXX | XXX |
| EV/Gross Profit | 1733.7x | XXX | — | XXX | XXX | XXX |
| P/E | (25.2x) | XXX | (23.9x) | XXX | XXX | XXX |
| EV/FCF | (41.6x) | XXX | (46.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Abivax Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Abivax Margins & Growth Rates
Abivax's revenue in the last 12 month grew by 698%.
Abivax's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $4.1M for the same period.
Abivax Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 698% | XXX | (26%) | XXX | XXX | XXX |
| EBITDA Margin | (5036%) | XXX | (4600%) | XXX | XXX | XXX |
| EBITDA Growth | (8%) | XXX | 10% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $4.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 128% | XXX | 110% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1773% | XXX | 1575% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 4135% | XXX | 3854% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 5335% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Abivax Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Praxis Precision Medicines | XXX | XXX | XXX | XXX | XXX | XXX |
| Kyowa Kirin | XXX | XXX | XXX | XXX | XXX | XXX |
| Fosun Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Huadong Medicine | XXX | XXX | XXX | XXX | XXX | XXX |
| Arrowhead Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Abivax M&A Activity
Abivax acquired XXX companies to date.
Last acquisition by Abivax was on XXXXXXXX, XXXXX. Abivax acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Abivax
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAbivax Investment Activity
Abivax invested in XXX companies to date.
Abivax made its latest investment on XXXXXXXX, XXXXX. Abivax invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Abivax
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Abivax
| When was Abivax founded? | Abivax was founded in 2013. |
| Where is Abivax headquartered? | Abivax is headquartered in France. |
| How many employees does Abivax have? | As of today, Abivax has over 69 employees. |
| Who is the CEO of Abivax? | Abivax's CEO is Marc de Garidel. |
| Is Abivax publicly listed? | Yes, Abivax is a public company listed on Nasdaq. |
| What is the stock symbol of Abivax? | Abivax trades under ABVX ticker. |
| When did Abivax go public? | Abivax went public in 2023. |
| Who are competitors of Abivax? | Abivax main competitors are Praxis Precision Medicines, Kyowa Kirin, Fosun Pharma, Huadong Medicine. |
| What is the current market cap of Abivax? | Abivax's current market cap is $9B. |
| What is the current revenue of Abivax? | Abivax's last 12 months revenue is $5M. |
| What is the current revenue growth of Abivax? | Abivax revenue growth (NTM/LTM) is 698%. |
| What is the current EV/Revenue multiple of Abivax? | Current revenue multiple of Abivax is 1730.1x. |
| Is Abivax profitable? | No, Abivax is not profitable. |
| What is the current EBITDA of Abivax? | Abivax has negative EBITDA and is not profitable. |
| What is Abivax's EBITDA margin? | Abivax's last 12 months EBITDA margin is (5036%). |
| What is the current EV/EBITDA multiple of Abivax? | Current EBITDA multiple of Abivax is (34.4x). |
| What is the current FCF of Abivax? | Abivax's last 12 months FCF is ($207M). |
| What is Abivax's FCF margin? | Abivax's last 12 months FCF margin is (4163%). |
| What is the current EV/FCF multiple of Abivax? | Current FCF multiple of Abivax is (41.6x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.